Free online – available from the Journal of Rheumatology

Long-lasting Remission of Severe Behçet’s Disease After the End of Infliximab Therapy. By I. Olivieri and colleagues. In: Journal of Rheumatology. 2009 Apr;36(4):855.

Infliximab is commonly known as Remicade. You can read more about this medicine at

Free online – available from the Portuguese Society of Rheumatology

The management of Behçet's syndrome. By Emire Seyahi, Izzet Fresko, Melike Melikoglu, and Hasan Yazici. In: Acta Reumatologica Portuguesa, 2006 Apr-Jun;31(2):125-31. (Article is in English.)


Behçet syndrome (BS) is a multisystem vasculitis characterized by skin and mucosa lesions and musculoskeletal, ocular, gastrointestinal, neurological and major vessel involvement. It is seen mainly in the Mediterranean basin, Middle East and the Far East. The disease runs a more severe course among young males and the severity diminishes with age. This review describes the management of this disease, which should be individualized and varies according to site and gender.

You can also listen to a free podcast of Dr Yazici’s lecture available from the American Behçet Disease Association.

The following abstract is now quite old but it gives some idea of Behçet's prevalence in Australia

Aust N Z J Ophthalmol. 1990 May;18(2):129-35. "Behçet's syndrome: ocular features in an Australian population." By D. Wakefield and P. McCluskey,  Laboratory of Ocular Immunology, School of Pathology, University of NSW, Australia.

Inflammatory eye disease (IED) is often the most severe manifestation of Behçet's syndrome (BS). This disease is a common cause of uveitis in Mediterranean countries, the Middle East and Japan. In order to ascertain the prevalence of this disease in Australia, we reviewed the aetiology of patients attending our uveitis clinic over a five-year period. Twelve of 426 patients with inflammatory eye disease had definite Behçet's syndrome. Four patients had anterior uveitis, four had posterior uveitis, four had retinal vasculitis and one also had optic neuritis. Although inflammatory eye disease was the initial clinical feature of Behçet's syndrome in only three of our patients, it was the feature that led to a definite diagnosis in all but one patient. The inflammatory eye disease of Behçet's syndrome was characteristically recurrent and severe with significantly decreased vision in 10 eyes, cataracts in six eyes, macula oedema in four eyes and glaucoma in two eyes. We conclude that Behçet's syndrome is a rare cause of inflammatory eye disease in Australia and is unlikely to be recognised as a distinct clinical entity prior to the onset of ocular involvement. The visual prognosis of ocular inflammation in Behçet's syndrome remains guarded despite the use of a variety of immunosuppressive agents.